Treatment of Moderate-to-Severe Psoriasis in Clinical Practice: A Survey of Spanish Dermatologists

被引:11
作者
Moreno-Ramirez, D. [1 ]
Fonseca, E. [2 ]
Herranz, P. [3 ]
Ara, M. [4 ]
机构
[1] Hosp Univ Virgen Macarena Sevilla, Serv Dermatol Med Quirurg & Venereol, Seville, Spain
[2] Complejo Hosp A Coruna, Serv Dermatol, Coruna, Spain
[3] Hosp Univ La Paz, Serv Dermatol, Madrid, Spain
[4] Hosp Clin Univ Lozano Blesa, Serv Dermatol, Zaragoza, Spain
来源
ACTAS DERMO-SIFILIOGRAFICAS | 2010年 / 101卷 / 10期
关键词
Psoriasis; Disease management; Survey; Dermatology; Spain;
D O I
10.1016/j.ad.2010.06.011
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background and objectives: Various treatment options are available for use in moderate-to-severe psoriasis and election is dependent upon the clinical criteria applied by the attending physician. We undertook a survey among dermatologists to assess the treatment of moderate-to-severe psoriasis currently used in clinical practice in Spain. Methods: A cross-sectional study was performed by sending a questionnaire to dermatologists in Spain who treat patients with moderate-to-severe psoriasis. The questionnaire comprised 33 items distributed in 6 sections: profile of the dermatologist, case load, patient profile, follow-up and management of the disease, treatment regimens, and assessment of pharmacological treatments. Results: According to the responses of the 164 dermatologists surveyed, 6.8% of patients seen in their clinics have moderate-to-severe psoriasis; of those, 45.8% receive systemic treatment and 22.9% are treated with biologic drugs. In many of those patients (50.2%), the dermatologist felt that a change in treatment was necessary; in 51.1% of cases, this change would be from systemic therapy to a biologic drug. The principal reason for the change (50.8%) would be lack of efficacy or the appearance of adverse effects. Efficacy and safety were considered essential criteria in the choice of an appropriate treatment (82.9% and 28.0% of dermatologists, respectively). Patient quality of life was also considered an essential consideration in choice of treatment by 28.0% of dermatologists. Conclusions: Optimal treatment for moderate-to-severe psoriasis should be effective and safe, and improve patient quality of life. This makes it essential to use drugs with an excellent efficacy and safety profile. (C) 2010 Elsevier Espana, S.L. and AEDV. All rights reserved.
引用
收藏
页码:858 / 865
页数:8
相关论文
共 50 条
[41]   Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi's Varicelliform Eruption [J].
Campanati, Anna ;
Molinelli, Elisa ;
Brisigotti, Valerio ;
Brancorsini, Donatella ;
Bobyr, Ivan ;
Diotallevi, Federico ;
Radi, Giulia ;
Offidani, Annamaria .
CASE REPORTS IN DERMATOLOGY, 2019, 11 :4-10
[42]   Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement [J].
Fargnoli, Maria Concetta ;
Bardazzi, Federico ;
Bianchi, Luca ;
Dapavo, Paolo ;
Fabbrocini, Gabriella ;
Gisondi, Paolo ;
Micali, Giuseppe ;
Offidani, Anna Maria ;
Pellacani, Giovanni ;
Skroza, Nevena ;
Angileri, Rosa Giuseppa ;
Burlando, Martina ;
Campanati, Anna ;
Carrera, Carlo Giovanni ;
Chiricozzi, Andrea ;
Conti, Andrea ;
Simone, Clara De ;
Di Lernia, Vito ;
Errichetti, Enzo ;
Galluzzo, Marco ;
Guarneri, Claudio ;
Lasagni, Claudia ;
Lembo, Serena ;
Loconsole, Francesco ;
Megna, Matteo ;
Musumeci, Maria Letizia ;
Prignano, Francesca ;
Richetta, Antonio Giovanni ;
Trovato, Emanuele ;
Venturini, Marina ;
Peris, Ketty ;
Pinton, Piergiacomo Calzavara .
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (10)
[43]   Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan [J].
Tada, Yayoi ;
Soliman, Ahmed M. ;
Ishii, Kanako ;
Sakuma, Ryuta ;
Pinter, Andreas ;
Davis, Matthew ;
Nunag, Dominic ;
Buessing, Marric ;
Puig, Luis ;
Imafuku, Shinichi .
EXPERIMENTAL DERMATOLOGY, 2024, 33 (05)
[44]   The management of moderate-to-severe chronic plaque psoriasis [J].
Tonini, Annalisa ;
Panduri, Salvatore ;
D'Erme, Angelo M. ;
Papadia, Francesca ;
Romaneli, Marco ;
Krueger, James G. ;
Chiricozzi, Andrea .
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2017, 152 (05) :447-457
[45]   Pregnancy outcomes in women with moderate-to-severe psoriasis [J].
Cohen-Barak, E. ;
Nachum, Z. ;
Rozenman, D. ;
Ziv, M. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2011, 25 (09) :1041-1047
[46]   Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis [J].
Romero-Jimenez, Rosa M. ;
Escudero-Vilaplana, Vicente ;
Baniandres Rodriguez, Ofelia ;
Garcia Martin, Estela ;
Mateos Mayo, Ana ;
Sanjurjo Saez, Maria .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (08) :792-796
[47]   Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis [J].
Verbenko, Dmitry A. ;
Karamova, Arfenya E. ;
Artamonova, Olga G. ;
Deryabin, Dmitry G. ;
Rakitko, Alexander ;
Chernitsov, Alexandr ;
Krasnenko, Anna ;
Elmuratov, Artem ;
Solomka, Victoria S. ;
Kubanov, Alexey A. .
JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (01) :1-12
[48]   Brodalumab for Moderate-to-Severe Psoriasis: A Comprehensive Review of Efficacy, Safety, and Clinical Positioning [J].
Babaei, Nickoulet ;
Gill, Minka ;
Cervantes, Mireya ;
Kim, Dahyeon ;
Yang, Seanna ;
Wu, Jashin J. .
BIOLOGICS-TARGETS & THERAPY, 2025, 19 :415-422
[49]   Gaps in moderate plaque psoriasis management: A survey of Saudi dermatologists [J].
Almohideb, Mohammad ;
Almohideb, Nora Abdulrahman .
JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2021, 10 (12) :4519-4524
[50]   Biologic Agents for Moderate-to-Severe Plaque Psoriasis Mechanisms of Action and Treatment Considerations [J].
Cantrell, Wendy ;
Kaler, Rhonda .
JOURNAL OF THE DERMATOLOGY NURSES ASSOCIATION, 2014, 6 (04) :178-196